Closest horizons of Hsp70 engagement to manage neurodegeneration

Artem A. Venediktov; Olga Yu Bushueva; Varvara A. Kudryavtseva; Egor A. Kuzmin; Aleksandra V. Moiseeva; Anna Baldycheva; Igor Meglinski; Gennadii A. Piavchenko

doi:10.3389/fnmol.2023.1230436

Closest horizons of Hsp70 engagement to manage neurodegeneration

Artem A. Venediktov, Olga Yu Bushueva, Varvara A. Kudryavtseva, Egor A. Kuzmin, Aleksandra V. Moiseeva, Anna Baldycheva^*, Igor Meglinski^*, Gennadii A. Piavchenko^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

Abstract

Our review seeks to elucidate the current state-of-the-art in studies of 70-kilodalton-weighed heat shock proteins (Hsp70) in neurodegenerative diseases (NDs). The family has already been shown to play a crucial role in pathological aggregation for a wide spectrum of brain pathologies. However, a slender boundary between a big body of fundamental data and its implementation has only recently been crossed. Currently, we are witnessing an anticipated advancement in the domain with dozens of studies published every month. In this review, we briefly summarize scattered results regarding the role of Hsp70 in the most common NDs including Alzheimer’s disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS). We also bridge translational studies and clinical trials to portray the output for medical practice. Available options to regulate Hsp70 activity in NDs are outlined, too.

Original language	English
Article number	1230436
Journal	Frontiers in Molecular Neuroscience
Volume	16
DOIs	https://doi.org/10.3389/fnmol.2023.1230436
Publication status	Published - 19 Sept 2023

Bibliographical note

© 2023 Venediktov, Bushueva, Kudryavtseva, Kuzmin, Moiseeva, Baldycheva, Meglinski and Piavchenko. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Funding: This study was supported by the Russian Science Foundation (project no. 23–25-00448, https://www.rscf.ru/project/23-25-00448/).

Keywords

Hsp70
amyotrophic lateral sclerosis
neurodegenerative diseases
neuropharmacology
Alzheimer’s disease

Access to Document

10.3389/fnmol.2023.1230436Licence: CC BY 4.0

fnmol-16-1230436.pdf
© 2023 Venediktov, Bushueva, Kudryavtseva, Kuzmin, Moiseeva, Baldycheva, Meglinski and Piavchenko. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Final published version, 1.26 MBLicence: CC BY 4.0

Cite this

@article{5fb5174c8fb34b5187d4810cc41cdd8c,

title = "Closest horizons of Hsp70 engagement to manage neurodegeneration",

abstract = "Our review seeks to elucidate the current state-of-the-art in studies of 70-kilodalton-weighed heat shock proteins (Hsp70) in neurodegenerative diseases (NDs). The family has already been shown to play a crucial role in pathological aggregation for a wide spectrum of brain pathologies. However, a slender boundary between a big body of fundamental data and its implementation has only recently been crossed. Currently, we are witnessing an anticipated advancement in the domain with dozens of studies published every month. In this review, we briefly summarize scattered results regarding the role of Hsp70 in the most common NDs including Alzheimer{\textquoteright}s disease (AD), Parkinson{\textquoteright}s disease (PD), and amyotrophic lateral sclerosis (ALS). We also bridge translational studies and clinical trials to portray the output for medical practice. Available options to regulate Hsp70 activity in NDs are outlined, too.",

keywords = "Hsp70, amyotrophic lateral sclerosis, neurodegenerative diseases, neuropharmacology, Alzheimer{\textquoteright}s disease",

author = "Venediktov, {Artem A.} and Bushueva, {Olga Yu} and Kudryavtseva, {Varvara A.} and Kuzmin, {Egor A.} and Moiseeva, {Aleksandra V.} and Anna Baldycheva and Igor Meglinski and Piavchenko, {Gennadii A.}",

note = "{\textcopyright} 2023 Venediktov, Bushueva, Kudryavtseva, Kuzmin, Moiseeva, Baldycheva, Meglinski and Piavchenko. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. Funding: This study was supported by the Russian Science Foundation (project no. 23–25-00448, https://www.rscf.ru/project/23-25-00448/). ",

year = "2023",

month = sep,

day = "19",

doi = "10.3389/fnmol.2023.1230436",

language = "English",

volume = "16",

}

TY - JOUR

T1 - Closest horizons of Hsp70 engagement to manage neurodegeneration

AU - Venediktov, Artem A.

AU - Bushueva, Olga Yu

AU - Kudryavtseva, Varvara A.

AU - Kuzmin, Egor A.

AU - Moiseeva, Aleksandra V.

AU - Baldycheva, Anna

AU - Meglinski, Igor

AU - Piavchenko, Gennadii A.

N1 - © 2023 Venediktov, Bushueva, Kudryavtseva, Kuzmin, Moiseeva, Baldycheva, Meglinski and Piavchenko. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. Funding: This study was supported by the Russian Science Foundation (project no. 23–25-00448, https://www.rscf.ru/project/23-25-00448/).

PY - 2023/9/19

Y1 - 2023/9/19

N2 - Our review seeks to elucidate the current state-of-the-art in studies of 70-kilodalton-weighed heat shock proteins (Hsp70) in neurodegenerative diseases (NDs). The family has already been shown to play a crucial role in pathological aggregation for a wide spectrum of brain pathologies. However, a slender boundary between a big body of fundamental data and its implementation has only recently been crossed. Currently, we are witnessing an anticipated advancement in the domain with dozens of studies published every month. In this review, we briefly summarize scattered results regarding the role of Hsp70 in the most common NDs including Alzheimer’s disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS). We also bridge translational studies and clinical trials to portray the output for medical practice. Available options to regulate Hsp70 activity in NDs are outlined, too.

AB - Our review seeks to elucidate the current state-of-the-art in studies of 70-kilodalton-weighed heat shock proteins (Hsp70) in neurodegenerative diseases (NDs). The family has already been shown to play a crucial role in pathological aggregation for a wide spectrum of brain pathologies. However, a slender boundary between a big body of fundamental data and its implementation has only recently been crossed. Currently, we are witnessing an anticipated advancement in the domain with dozens of studies published every month. In this review, we briefly summarize scattered results regarding the role of Hsp70 in the most common NDs including Alzheimer’s disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS). We also bridge translational studies and clinical trials to portray the output for medical practice. Available options to regulate Hsp70 activity in NDs are outlined, too.

KW - Hsp70

KW - amyotrophic lateral sclerosis

KW - neurodegenerative diseases

KW - neuropharmacology

KW - Alzheimer’s disease

UR - http://www.scopus.com/inward/record.url?scp=85173595769&partnerID=8YFLogxK

UR - https://www.frontiersin.org/articles/10.3389/fnmol.2023.1230436/full

U2 - 10.3389/fnmol.2023.1230436

DO - 10.3389/fnmol.2023.1230436

M3 - Review article

SN - 1662-5099

VL - 16

JO - Frontiers in Molecular Neuroscience

JF - Frontiers in Molecular Neuroscience

M1 - 1230436

ER -

Closest horizons of Hsp70 engagement to manage neurodegeneration

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this